系膜增生性肾小球肾炎 中国就医指南

Mesangial proliferative glomerulonephritis (MesPGN) is a primary glomerular disease characterized by diffuse or focal hypercellularity of the mesangial area—due to increased mesangial cell number and/or expanded mesangial matrix—without significant endocapillary proliferation, crescent formation, or basement membrane duplication. It is a histopathological diagnosis typically confirmed via renal biopsy and classified under the broader umbrella of IgA nephropathy (IgAN) when immunoglobulin A (IgA) deposits dominate, or as non-IgA MesPGN when other immune complexes (e.g., IgG or IgM) predominate. Pathogenesis involves dysregulated mucosal immunity, abnormal glycosylation of IgA1 leading to autoantibody formation, immune complex deposition in the mesangium, and subsequent activation of complement (particularly the lectin and alternative pathways), triggering local inflammation, mesangial cell activation, cytokine release (e.g., PDGF, TGF-β), and extracellular matrix expansion. This cascade results in progressive glomerular sclerosis and, in some cases, tubulointerstitial fibrosis. Epidemiologically, MesPGN accounts for approximately 10–25% of all native kidney biopsies in East Asia, with higher prevalence in China, Japan, and Korea—likely reflecting both genetic susceptibility (e.g., HLA-DQ/DR variants) and environmental triggers such as recurrent mucosal infections. Globally, it is less common in Caucasian populations (<5% of biopsies). Peak incidence occurs in adolescents and young adults (ages 15–35), with a slight male predominance. Key risk factors include upper respiratory or gastrointestinal infections preceding onset, family history of IgAN or chronic kidney disease, smoking, obesity, uncontrolled hypertension, and persistent microscopic hematuria or proteinuria (>0.5 g/day). While many patients remain stable for years, ~20–30% progress to chronic kidney disease (CKD) stage 3+ over 10–20 years; a subset develops end-stage kidney disease requiring dialysis or transplantation. Quality of life is significantly impacted—not only by physical symptoms (fatigue, edema, hypertension-related headaches, reduced exercise tolerance) but also by psychological burden: anxiety about disease progression, treatment adherence challenges (e.g., long-term corticosteroids or immunosuppressants), dietary restrictions (low-sodium, low-protein), financial strain from repeated monitoring and therapy, and occupational limitations due to fatigue or frequent clinic visits. Patients often report diminished social engagement, sleep disturbances, and reduced health-related quality of life scores on validated instruments (e.g., KDQOL-SF™), particularly in domains of physical functioning, emotional well-being, and symptom burden.

# 系膜增生性肾小球肾炎治疗方案与费用明细（肾内科）

一、保守/药物治疗（一线方案）

适用于轻中度蛋白尿（<3.5g/d）、eGFR ≥60mL/min/1.73m²、无新月体形成者：

• •基础治疗：ACEI/ARB（如缬沙坦）+低盐优质蛋白饮食，年药费 1,200–3,600元
• •免疫抑制治疗（病理证实中重度系膜增生伴IgA沉积）：

- 检查费（含肾穿刺活检术、24h尿蛋白、血清IgA/C3、eGFR动态监测）：4,200–6,500元/次

二、介入/核心治疗（限难治性进展型）

适用于激素抵抗、6月内eGFR下降≥15mL/min/1.73m²或伴局灶节段性硬化者：

• •利妥昔单抗静脉输注（375mg/m²×4次，间隔1周）：药费+输注管理 48,000–62,000元/疗程
• •术前检查（含凝血功能、乙肝/HCV/EBV筛查、心超）：2,800–4,100元

三、晚期/并发症/耐药方案

终末期（eGFR <15mL/min/1.73m²）或反复复发者：

• •维持性血液透析（每周3次）：年均费用 72,000–96,000元（含医保报销后自付）
• •肾移植评估及等待期管理：术前评估费 15,000–22,000元；移植手术费（含供体匹配、手术、首年免疫抑制剂） 280,000–350,000元

方案快速选择指南

• •预算有限/初诊轻症：首选ACEI/ARB+生活方式干预（年总成本≤5,000元）
• •中高预算/病理中重度：霉酚酸酯联合激素（年总成本约6–8万元）
• •快速进展/耐药：利妥昔单抗方案（单疗程投入5–6万元，显著延缓肾衰）
• •终末期患者：透析为刚需；经济条件允许可优先评估肾移植